MAIA Biotechnology Announces $2.25M Private Placement Deal

MAIA Biotechnology, Inc. ( (MAIA) ) has shared an announcement.

On December 16, 2025, MAIA Biotechnology, Inc. entered into a Securities Purchase Agreement with accredited investors and directors for a private placement of common stock and warrants worth approximately $2.25 million. The director participation aligns leadership interests with shareholders, and the funds will support Phase II clinical trials of the THIO-101 program as well as general working capital. The transaction is expected to close on December 18, 2025, pending standard closing conditions.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted immunotherapies for cancer. Its primary program, ateganosine (THIO), is a novel telomere-targeting agent in clinical trials for treating telomerase-positive non-small cell lung cancer (NSCLC).

Average Trading Volume: 710,607

Technical Sentiment Signal: Sell

Current Market Cap: $45.55M

See more data about MAIA stock on TipRanks’ Stock Analysis page.